BR9909712A - Composição compreendendo l-carnitina ou um alcanoil-l-carnitina e nadh e/ou madph - Google Patents

Composição compreendendo l-carnitina ou um alcanoil-l-carnitina e nadh e/ou madph

Info

Publication number
BR9909712A
BR9909712A BR9909712-5A BR9909712A BR9909712A BR 9909712 A BR9909712 A BR 9909712A BR 9909712 A BR9909712 A BR 9909712A BR 9909712 A BR9909712 A BR 9909712A
Authority
BR
Brazil
Prior art keywords
carnitine
nadh
composition
alkanoyl
madph
Prior art date
Application number
BR9909712-5A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Heal Thscience S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Heal Thscience S P A filed Critical Sigma Tau Heal Thscience S P A
Publication of BR9909712A publication Critical patent/BR9909712A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO COMPREENDENDO L-CARNITINA OU UM ALCANOIL L-CARNITINA E NADH E/OU NADPH"<D>. Apresenta-se uma composição que compreende L-carnitina ou um alcanoil L-carnitina ou o sal farmacologicamente aceitável deste e NADH e/ou NADPH, útil como um suplemento dietético para indivíduos empenhados em exercício físico extenuante ou indivíduos astênicos e, como um medicamento para o tratamento da síndrome da fadiga crónica e doença de Parkinson.
BR9909712-5A 1998-04-17 1999-04-14 Composição compreendendo l-carnitina ou um alcanoil-l-carnitina e nadh e/ou madph BR9909712A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000238A IT1299161B1 (it) 1998-04-17 1998-04-17 Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
PCT/IT1999/000088 WO1999053921A1 (en) 1998-04-17 1999-04-14 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph

Publications (1)

Publication Number Publication Date
BR9909712A true BR9909712A (pt) 2000-12-26

Family

ID=11405812

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909712-5A BR9909712A (pt) 1998-04-17 1999-04-14 Composição compreendendo l-carnitina ou um alcanoil-l-carnitina e nadh e/ou madph

Country Status (17)

Country Link
EP (1) EP1071424A1 (pt)
JP (1) JP2002512191A (pt)
KR (1) KR20010042765A (pt)
CN (1) CN1299283A (pt)
AU (1) AU750645B2 (pt)
BR (1) BR9909712A (pt)
CA (1) CA2328331A1 (pt)
EE (1) EE200000601A (pt)
HU (1) HUP0101914A3 (pt)
IL (1) IL139014A0 (pt)
IS (1) IS5663A (pt)
IT (1) IT1299161B1 (pt)
NO (1) NO20005128L (pt)
PL (1) PL343482A1 (pt)
SK (1) SK15442000A3 (pt)
TR (1) TR200002894T2 (pt)
WO (1) WO1999053921A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252309B2 (en) 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (de) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
MX2009012042A (es) * 2007-05-11 2009-12-01 Sigma Tau Ind Farmaceuti Gel util para el suministro de ingredientes activos cosmeticos.
WO2011022786A1 (en) * 2009-08-31 2011-03-03 Pharmaqest Pty Ltd Methods for diagnosis and treatment of chronic fatigue syndrome
CN104306390A (zh) * 2014-10-23 2015-01-28 苏州人本药业有限公司 还原型辅酶ⅱ的用途
CN104840479A (zh) * 2015-02-17 2015-08-19 苏州人本药业有限公司 Nadph在制备治疗心脏疾病药物中的应用
ES2786774B2 (es) * 2017-12-22 2022-03-04 Bontac Bio Eng Shenzhen Co Ltd Composición para compuesto de coenzima NADH, preparación y aplicación del mismo.
PL3755160T3 (pl) 2018-04-20 2022-02-14 Pacotrade Ag Urządzenie do rozdrabniania głęboko mrożonych środków spożywczych przygotowanych w formie bloku
CN109170907A (zh) * 2018-08-30 2019-01-11 泓博元生命科技（深圳）有限公司 一种含有nmn的组合物、应用及运动饮料的制备方法
CN109105702A (zh) * 2018-08-30 2019-01-01 泓博元生命科技（深圳）有限公司 一种含有nadh的组合物、应用及能量补充剂的制备方法
CA3115743A1 (en) * 2018-10-10 2020-04-16 So Ngor Sally LEUNG Health-care product composition for enriching asthenic disease, preparation method therefor and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (pt) * 1964-12-04
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
JPH09110708A (ja) * 1995-08-11 1997-04-28 Taisho Pharmaceut Co Ltd 滋養強壮用生薬配合製剤
JPH0959161A (ja) * 1995-08-23 1997-03-04 Taisho Pharmaceut Co Ltd 疲労改善用組成物
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JPH10175856A (ja) * 1996-10-14 1998-06-30 Taisho Pharmaceut Co Ltd 疲労改善剤

Also Published As

Publication number Publication date
EE200000601A (et) 2002-04-15
IS5663A (is) 2000-10-13
CA2328331A1 (en) 1999-10-28
KR20010042765A (ko) 2001-05-25
TR200002894T2 (tr) 2001-01-22
WO1999053921A1 (en) 1999-10-28
NO20005128L (no) 2000-12-18
SK15442000A3 (sk) 2001-06-11
IT1299161B1 (it) 2000-02-29
HUP0101914A3 (en) 2002-12-28
NO20005128D0 (no) 2000-10-12
JP2002512191A (ja) 2002-04-23
IL139014A0 (en) 2001-11-25
HUP0101914A2 (hu) 2002-03-28
ITRM980238A1 (it) 1999-10-17
ITRM980238A0 (it) 1998-04-17
PL343482A1 (en) 2001-08-27
AU750645B2 (en) 2002-07-25
CN1299283A (zh) 2001-06-13
AU3442899A (en) 1999-11-08
EP1071424A1 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
BR9909712A (pt) Composição compreendendo l-carnitina ou um alcanoil-l-carnitina e nadh e/ou madph
BR0309855A (pt) Pirazolpiridinas substituìdas com carbamato
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0410503B8 (pt) composição tópica e uso da composição
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
BRPI0510761A (pt) métodos de tratar um paciente afligido com pelo menos uma enfermidade e de reduzir ou eliminar rugas
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
BRPI0411295A (pt) compostos e seu uso na terapia
AR024820A1 (es) Composicion para la prevencion de fatiga muscular y adaptacion del musculo esqueletal a un ejercicio extenuante.
BR0315169A (pt) Referência cruzada a pedidos de patente relacionados
BR0006045A (pt) Composição que compreende uma carnitina e glutationa, útil para aumentar a absorção de glutationa e para sinergizar seus efeitos
BR0307126A (pt) Uso de beldroega para tratar rugas faciais
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
ATE265216T1 (de) Nahrungsergänzung zur verbesserung des muskelenergiestoffwechsels, enthaltend alkanoyl- carnitine und ribose
BR0006076A (pt) Composição contento carnitina e fosfato de inositol útil como suplemento dietético ou medicamento
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
MX9703810A (es) Medicamento que comprende un derivado de carnitinapara tratar la enfermedad de alzheimer en pacientes con inicio prematuro.
BR9813856A (pt) Processos para o tratamento de uma paciente que sofre de sìndrome pré-menstrual, depressão, anemia, enxaquecas ou distúrbios alimentares e para aumentar o nìvel de serotonin em um ser humano com nìvel reduzido do mesmo no fluxo sanguìneo e composição
HK1078460A1 (en) Use of l-carnitine, actyl l-carnitine and propionyl l-carnitine in the manufacture of a combined medicament for the treatment of oligoasthenoteratospermia
BRPI0417230A (pt) bactéria produtora da l-treonina pertencente ao gênero escherichia, e, método para produzir l-treonina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O,6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.